TABLE 4 .
Prevalence of combinations of ESBL, CTX-M-15, fluoroquinolone resistance, co-trimoxazole resistance, and tetracycline resistance among isolates included in this study (n = 78)
| Subset | Subset definitiona | Total no. (%) of Indian isolates |
No. of isolates (%) associated with infection type: |
||
|---|---|---|---|---|---|
| Pyelonephritis (n = 30) |
Septicemia (n = 27) |
Skin and soft tissue infections (n = 21) |
|||
| 1 | ESBL+ CTX-M-15+ | 60 (77) | 21 (70) | 23 (85) | 16 (76) |
| 2 | ESBL+ CTX-M-15+ Tem+ | 30 (38) | 11 (37) | 12 (43) | 7 (33) |
| 3 | CTX-M-15+, fluoroquinolone resistant | 57 (73) | 20 (67) | 22 (81) | 15 (71) |
| 4 | CTX-M-15+, fluoroquinolone resistant, co-trimoxazole resistant | 44 (56) | 17 (56) | 17 (63) | 10 (48) |
| 5 | CTX-M-15+, fluoroquinolone susceptible, co-trimoxazole resistant | 2 (3) | 1 (3) | 1 (4) | 0 (0) |
| 6 | CTX-M-15+, fluoroquinolone resistant, co-trimoxazole susceptible | 13 (17) | 3 (10) | 5 (18) | 5 (24) |
| 7 | CTX-M-15+, fluoroquinolone susceptible, co-trimoxazole susceptible | 3 (4) | 0 (0) | 1 (4) | 2 (10) |
| 8 | CTX-M-15+, fluoroquinolone resistant, co-trimoxazole resistant, tetracycline resistant | 39 (50) | 17 (56) | 16 (57) | 6 (29) |
| 9 | CTX-M-15+, fluoroquinolone resistant, co-trimoxazole resistant, tetracycline susceptible | 4 (5) | 0 (0) | 0 (0) | 4 (19) |
| 10 | CTX-M-15−, fluoroquinolone susceptible | 6 (8) | 4 (13) | 2 (7) | 0 (0) |
a
Tem, temoniera-beta-lactamase.